Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome

9 Jul 2024

Abstract excerpt

Myelodysplastic syndromes (MDS) are heterogeneous diseases with variable clinical outcome and an inherent risk of progression to acute myeloid leukemia (AML). Allogeneic hematopoietic cell transplantation (alloHCT) is the standard curative treatment [ 1 ] but the requirement for pre-transplant induction therapy remains unclear in MDS. In 2022, the new entity MDS/AML was introduced by the European LeukemiaNet...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Hematopoietic Stem Cell Transplantation
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38982155
DOI: 10.1038/s41409-024-02365-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndromePMID 38982155Read ↗

Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.Semantic proximity Read ↗

Myelodysplastic Syndromes: A New Decade.Semantic proximity Read ↗

Acute Myeloid Leukemia Patients With Myelodysplasia-Related Gene Mutations Benefit From Post-Transplant Hypomethylating Agent Maintenance.Semantic proximity Read ↗

A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.Semantic proximity Read ↗

Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.Semantic proximity Read ↗

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative NeoplasmsSemantic proximity Read ↗

Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes.Semantic proximity Read ↗

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.Semantic proximity Read ↗

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment LandscapeSemantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Critical Role of Molecular-Based Stratification in Low-Risk Myelodysplastic Syndrome with Direct Progression to Acute Myeloid Leukemia: A Case Report.Semantic proximity Read ↗

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.